Clinical Roundup: Gene-Edited Therapies for Beta...
Jul. 26, 2023
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Shanghai Bangyao Biotechnology Co., Ltd. - BioRay Laboratories
Main focus: Gene editing of haematopoietic stem cells and next generation CAR-T cells
Company stage: Clinical
Diseases: Beta-thalassemia, alpha-thalassemia, multiple haematological and solid tumours
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Shanghai, China
Website: https://www.bioraylab.com/
Bioray Laboratories is a Shanghai-based company focusing on the development of haematopoietic stem cell (HSCs)-based medicines as well as next generation CAR-T cell-based therapies. The company uses CRISPR to knock out various targets within the genomes of HSCs and CAR-T cells. Currently, the company is conducting multiple clinical trials in which CRISPR-Cas9 is being used for the treatment of beta-thalassemia and B-cell lymphomas using CAR-T.
Tags
Shanghai Bangyao Biotechnology Co., Ltd. - BioRay Laboratories
Related News and Updates
Clinical Trials
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
B-cell Acute Lymphoblastic Leukemia, B-ALL, (NCT03232619)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd.
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-cell Malignancies, (NCT03229876)
Sponsors:
Bioray Laboratories - Shanghai Bangyao Biotechnology Co., Ltd.
Sponsors:
Bioray Laboratories - Shanghai Bangyao Biotechnology Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
